retatrutide phase 2 type 2 diabetes trial Reta clinical data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in 3 trials for metabolic health — targeting GLP-1, GIP Lilly's triple agonist, retatrutide, successful
Pay in 4 interest-free payments of $5.14 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6



01053-X/asset/68ad1d8b-bb7e-4ca0-8f89-99384d885ca3/main.assets/gr2.jpg)






















